Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT for HPV+ LSIL/CIN1
NCT02631863Phase 2Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aminolevulinic acid in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Mar 2016; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT02631863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631863.